Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
NHLBI Catalyze program supports early-stage research to identify and characterize small molecule, biologic, and combination product therapeutic candidates for heart, lung, blood, and sleep (HLBS) disorders.
Funder: National Institutes of Health
Due Dates: June 18, 2025 | October 21, 2025 | February 11, 2026 | June 18, 2026 | October 21, 2026 | February 11, 2027 | June 17, 2027 | October 21, 2027 | December 23, 2027 (final closing)
Funding Amounts: Up to $400,000 direct costs per year; maximum project period is 2 years; cost matching of at least 25% of direct federal costs required.
Summary: Supports early-stage translational research to identify and characterize lead therapeutic candidates and combination products for heart, lung, blood, and sleep (HLBS) diseases.
Key Information: Applications must include both a cost match and a letter of support from an Accelerator Partner; clinical trials are not allowed.
Description
This opportunity, offered by the National Heart, Lung, and Blood Institute (NHLBI) as part of the NIH Catalyze Program, aims to support early-stage translational research focused on identifying and characterizing lead small molecules, biologics, or combination products for the treatment of heart, lung, blood, and sleep (HLBS) diseases and disorders. The program is designed to bridge the gap between basic science discoveries and preclinical development, enabling researchers to advance therapeutic candidates to a stage suitable for further preclinical testing or independent development.
Eligible projects should demonstrate novelty, a strong biological rationale with preliminary data, and clear relevance to therapy development for HLBS conditions. The initiative emphasizes milestone-driven project management, robust reproducibility, and a collaborative approach involving commercialization expertise.
